BioSpace News Archive

MicroPort Scientific Corporation announced on October 4th, 2021, through its critical care subsidiary, MicroPort Surgical B.V., has acquired 100% of the equity held by existing shareholders of Hemovent GmbH for a total cash consideration of up to €123 million.

CCT Research announced today plans to operate as a study site for, and begin enrolling participants into, the global Phase 3 RENOIR (RSV vaccine Efficacy study in older adults Immunized against RSV disease) in the Omaha and Phoenix markets.

Progenity, Inc. (“Progenity”) (Nasdaq: PROG), an innovative biotechnology company, today announced that it has entered into a definitive agreement with several institutional investors for the purchase and sale, in a registered direct offering priced at-the-market under Nasdaq rules, of 13,333,334 shares of the Company’s common stock, at a purchase price of $1.50 per share

With more than 300 patients treated compassionately with ACP-01 for ischemic cardiomyopathy, dilated cardiomyopathy, vascular dementia, COPD, and pulmonary hypertension, in this one-minute segment Peter recounts how his chest pain dissipated one week after his stem cell treatment, and he recounts how he felt like his life was back to normal after six weeks.

The Barbara Ann Karmanos Cancer Institute and KSP Specialty Pharmacy are pleased to announce the launch of new services and a new website: www.ksppharmacy.org.

Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today published the first data to demonstrate the anti-inflammatory activity of XENLETA® (lefamulin).

CorMedix Inc., a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, announced changes to its executive leadership team.

T2 Biosystems, Inc. announced that the Biomedical Advanced Research and Development Authority, part of the office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services, has exercised contract Option 2A providing an additional $6.4 million of funding for the multiple year cost share contract between BARDA and T2 Biosystems.

STRATA Skin Sciences, Inc., a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, announced that Mr. Christopher Lesovitz, STRATA’s current Controller, has been named Chief Financial officer.

CONMED Corporation (NYSE: CNMD) today announced that it will report financial results for the third quarter 2021 after the market close on October 27, 2021.